Evidence map›Paper›PMID 40589559›Full record

ArticleSurgical case reports2025

Immune Checkpoint Inhibitor-Related Aortitis Treated with Nivolumab for Esophageal Squamous Cell Carcinoma.

Norihiro Akimoto, Tsutomu Sato, Sho Sato, Hayato Watanabe, Akikazu Yago, Kohei Kasahara, Kenki Segami, Yusuke Suwa, Masakatsu Numata, Takafumi Kumamoto and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Norihiro AkimotoDepartment of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan.
Tsutomu SatoDepartment of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan.
Sho SatoDepartment of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan.
Hayato WatanabeDepartment of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan.
Akikazu YagoDepartment of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan.
Kohei KasaharaDepartment of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan.
Kenki SegamiDepartment of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan.
Yusuke SuwaDepartment of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan.
Masakatsu NumataDepartment of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan.
Takafumi KumamotoDepartment of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan.
Aya SaitoDepartment of Surgery, Yokohama City University, Yokohama, Kanagawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlthough immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) are widely recognized, ICI-related aortitis is very rare and challenging to diagnose. CASE PRESENTATION: A 70-year-old man with esophageal squamous carcinoma recurring after esophagectomy received paclitaxel therapy after nivolumab therapy. Nivolumab therapy was administered for 26 months; however, no adverse events occurred during treatment. One month after the initiation of paclitaxel therapy, the patient developed a fever lasting for 2 weeks. Thoracoabdominal contrast-enhanced computed tomography (CT) revealed aortic wall thickening and increased fat density in the descending thoracic aorta; however, no other cause of inflammation was detected. Further examination ruled out infectious or autoimmune disease, and the patient was eventually diagnosed with ICI-related aortitis. Methylprednisolone was administered intravenously at a dose of 80 mg, and the fever subsided on the second day after administration. As the inflammation improved, methylprednisolone was switched to oral prednisolone, and the dose was gradually tapered without symptom relapse. Two months after diagnosis, a follow-up CT scan confirmed the resolution of both aortic wall thickening and the increased fat density.

conclusionsICI-related aortitis should be considered as a differential diagnosis for unexplained fever after ICI administration.

Indexed as

esophageal cancerimmune-related adverse eventsnivolumab

Identifiers

PMID40589559
PMCPMC12208728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.